Content

Welcome to the CJU website » LOG IN

Details

Using darolutamide in advanced prostate cancer: How I Do It
Urology Centers of Alabama, Homewood, Alabama, USA
HOWIDOIT
Jun 2021 (Vol. 28, Issue 3, Pages( 10673 - 10677)
PMID: 34129460

Abstract

Text-Size + 

  • Darolutamide is a nonsteroidal androgen inhibitor FDA approved for the treatment of castration-resistant non-metastatic prostate cancer (nmCRPC). After decades of offering androgen deprivation therapy (ADT) alone or first-generation androgen receptor blockers for patients whose PSA was rising despite castrate levels of testosterone, there are now three different treatment options to add to ADT. These include apalutamide approved in February 2018, enzalutamide FDA approved in June 2018, and darolutamide approved July 2019. Each of these androgen receptor pathway blockers, when added to ADT or surgical orchiectomy, prolongs metastasis-free-survival (MFS) and median survival (MS). This paper focuses on the use of the newest approved agent in this class, darololutmide.

Current Issue

June 2021, Vol.28 No.3
canadian journal of urology